NF-κB-related genetic diseases

Cell Death and Differentiation

Volumn 13, Issue 5, 2006, Pages 843-851

  Courtois, Gilles ^a   Smahi, A ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

CYLD; Cylindromatosis; Incontinentia pigmenti, anhidrotic ectodermal dysplasia with immunodeficiency; NEMO; NF B

Indexed keywords

I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; PHOSPHOTRANSFERASE; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 3; CYLD PROTEIN, HUMAN; I KAPPA B; I KAPPA B KINASE; IKBKG PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

ALBERS SCHOENBERG DISEASE; ANHIDROTIC ECTODERMAL DYSPLASIA; BACTERIAL INFECTION; BONE MASS; CELL STIMULATION; CYLINDROMA; DISEASE ASSOCIATION; EPIDERMIS; GENE ACTIVATION; GENE DELETION; GENE FUNCTION; GENE MUTATION; GENE REARRANGEMENT; HISTOGENESIS; HOMEOSTASIS; HUMAN; IMMUNE DEFICIENCY; IN VIVO STUDY; INCONTINENTIA PIGMENTI; INNATE IMMUNITY; LYMPH VESSEL; LYMPHEDEMA; MISSENSE MUTATION; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TRICHOEPITHELIOMA; ANIMAL; BIOLOGICAL MODEL; GENE EXPRESSION REGULATION; GENETIC DISORDER; GENETICS; METABOLISM;

BACTERIA (MICROORGANISMS); STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; GENE EXPRESSION REGULATION; GENETIC DISEASES, INBORN; I-KAPPA B KINASE; I-KAPPA B PROTEINS; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, BIOLOGICAL; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 33645987311     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401841     Document Type: Review

References (76)

1. Karin M and Ben-Neriah Y (2000) Phosphorylation meets ubiquitination : the control of NF-κB activity. Ann. Rev. Immunol. 18: 621-663
2. Hayden MS and Ghosh S (2004) Signaling to NF-κB. Genes Dev. 18: 2195-2224
3. Israël A (2000) The IKK complex: An integrator of all signals that activate NF-κB? Trends Cell Biol. 10: 129-133
4. Chen G, Cao P and Goeddel DV (2002) TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol. Cell 9: 401-410
5. Ducut Sigala JL, Bottero V, Young DB, Shevchenko A, Mercurio F and Verma IM (2004) Activation of transcription factor NF-κB requires ELKS, an IκB kinase regulatory subunit. Science 304: 1963-1967
6. Yamaoka S, Courtois G, Bessia C, Whiteside ST, Weil R, Agou F, Kirk HE, Kay RJ and Isral A (1998) Complementation cloning of NEMO, a component of the IκB kinase complex essential for NF-κB activation. Cell 93: 1231-1240
7. Chu ZL, Shin YA, Yang JM, DiDonato JA and Ballard DW (1999) IKKγ mediates the interaction of cellular IκB kinases with the tax transforming protein of human T cell leukemia virus type 1. J. Biol. Chem. 274: 15297-15300
8. Zhang SQ, Kovalenko A, Cantarella G and Wallach D (2000) Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKγ) upon receptor stimulation. Immunity 12: 301-311
9. Agou F, Traincard F, Vinolo E, Courtois G, Yamaoka S, Israël A and Véron M (2004) The trimerization domain of NEMO is composed of the interacting C-terminal CC2 and LZ coiled-coil subdomains. J. Biol. Chem. 279: 27861-27869
10. Makris C, Roberts JL and Karin M (2002) The carboxyl-terminal region of IκB kinase γ (IKKγ) is required for full IKK activation. Mol. Cell. Biol. 22: 6573-6581
11. Jin D and Jeang KT (1999) Isolation of full-length cDNA and chromosomal localization of human NF-κB modulator NEMO to Xq28. J. Biochem. Sci. 6: 115-120
12. Pomerantz JL and Baltimore D (2002) Two pathways to NF-κB. Mol. Cell. 10: 693-695
13. Landi SJ and Donnai D (1993) Incontinentia pigmenti (Bloch-Sulzberger syndrome). J. Med. Genet. 30: 53-59
14. Berlin AL, Paller AS and Chan LS (2002) Incontinentia pigmenti: A review and update on the molecular basis of pathophysiology. J. Am. Acad. Dermatol. 47: 169-187
15. Manago S and Barbagallo A (1993) Incontinentia pigmenti: Clinical and neuroradiologic features. Brain Dev. 15: 362-366
16. Lee AG, Goldberg MF, Gillard JH, Barker PB and Bryan RN (1995) Intracranial assessment of incontinentia pigmenti using magnetic resonance imaging, angiography, and spectroscopic imaging. Arch. Pediatr. Adolesc. Med. 149: 573-580
17. Hennel SJ, Ekert PG, Volpe JJ and Inder TE (2003) Insights into the pathogenesis of cerebral lesions in incontinentia pigmenti. Pediatr. Neurol. 29: 148-150
18. Coleman R, Genet SA, Harper JI and Wilkie AO (1993) Interaction of incontinentia pigmenti and factor VIII mutations in a female with biased X inactivation, resulting in haemophilia. J. Med. Genet. 30: 497-500
19. Smahi A, Courtois G, Vabres P, Yamaoka S, Heuertz S, Munnich A, Israël A, Heiss NS, Klauck SM, Kioschis P, Wiemann S, Poustka A, Esposito T, Bardaro T, Gianfrancesco F, Ciccodicola A, D'Urso M, Woffendin H, Jakins T, Donnai D, Stewart H, Kenwrick SJ, Aradhya S, Yamagata T, Levy M, Lewis RA and Nelson DL (2000) Genomic rearrangement in NEMO impairs NF-κB activation and is a cause of incontinentia pigmenti. Nature 405: 466-472
20. Aradhya S, Bardaro T, Galgoczy P, Yamagata T, Esposito T, Patlan H, Ciccodicola A, Munnich A, Kenwrick S, Platzer M, D'Urso M and Nelson DL (2001) Multiple pathogenic and benign genomic rearrangements occur at a 35 kb duplication involving the NEMO and LAGE2 genes. Hum. Mol. Genet. 10: 2557-2567
21. Aradhya S, Woffendin H, Jakins T, Bardaro T, Esposito T, Smahi A, Shaw C, Levy M, Munnich A, D'Urso M, Lewis RA, Kenwrick S and Nelson DL (2001) A recurrent deletion in the ubiquitously expressed NEMO (IKK-γ) gene accounts for the vast majority of incontinentia pigmenti mutations. Hum. Mol. Genet. 10: 2171-2719
22. Fusco F, Bardaro T, Fimiani G, Mercadante V, Miano M, Falco G, Israël A, Courtois G, D'Urso M and Ursini MV (2004) Molecular analysis of the genetic defect in a large cohort of IP patients and identification of novel NEMO mutations interfering with NF-κB activation. Hum. Mol. Genet. 13: 1763-1773
23. Kenwrick S, Woffendin H, Jakins T, Shuttleworth SG, Mayer E, Greenhalgh L, Whittaker J, Rugolotto S, Bardaro T, Esposito T, D'Urso M, Soli F, Turco A, Smahi A, Hamel-Teillac D, Lyonnet S, Bonnefont JP, Munnich A, Aradhya S, Kashork CD, Shaffer LG, Nelson DL, Levy M and Lewis RA (2001) Survival of male patients with incontinentia pigmenti carrying a lethal mutation can be explained by somatic mosaicism or Klinefelter syndrome. Am. J. Hum. Genet. 69: 1210-1217
24. van Leeuwen RL, Wintzen M and van Praag MC (2000) Incontinentia pigmenti: An extensive second episode of a 'first-stage' vesicobullous eruption. Pediatr. Dermatol. 17: 70-74
25. Bodak N, Hadj-Rabia S, Hamel-Teillac D, de Prost Y and Bodemer C (2003) Late recurrence of inflammatory first-stage lesions in incontinentia pigmenti: An unusual phenomenon and a fascinating pathologic mechanism. Arch. Dermatol. 139: 201-204
26. Frix CD and Bronson DM (1986) Acute miliary tuberculosis in a child with anhidrotic ectodermal dysplasia. Pediatr. Dermatol. 3: 464-467
27. Sitton JE and Reimund EL (1992) Extramedullary hematopoieisis of the cranial dura and anhidrotic ectodermal dysplasia. Neuropediatrics 23: 108-110
28. Abinun M, Spickett G, Appleton AL, Flood T and Cant AJ (1996) Anhidrotic ectodermal dysplasia associated with specific antibody deficiency. Eur. J. Pediatr. 155: 146-147
29. Schneider P, Kalhoff H, Horneff G, Wahn V and Diekmann L (1999) Polysaccharide specific humoral immunodeficiency in ectodermal dysplasia. Case report of a boy with two affected brothers. Klin. Padiatr. 211: 459-461
30. Zonana J, Elder ME, Schneider LC, Orlow SJ, Moss C and Golabi M (2000) A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKKγ(NEMO). Am. J. Hum. Genet. 67: 1555-1562
31. Döffinger R, Smahi A, Bessia C, Geissmann F, Feinberg J, Durandy A, Bodemer C, Kenwrick S, Dupuis-Girod S, Blanche S, Wood P, Rabia SH, Headon DJ, Overbeek PA, Le Deist F, Holland SM, Belani K, Kumararatne DS, Fischer A, Shapiro R, Conley ME, Reimund E, Kalhoff H, Abinun M, Munnich A, Israël A, Courtois G and Casanova JL (2001) X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-κB signaling. Nat. Genet. 27: 277-285
32. Aradhya S, Courtois G, Rajkovic A, Lewis AL, Levy M, Israël A and Nelson DL (2001a) Atypical forms of Incontinentia pigmenti in male individuals result from mutations of a cytosine tract in exon 10 of NEMO (IKK-γ). Am. J. Hum. Genet. 68: 765-771
33. Jain A, Ma CA, Liu S, Brown M, Cohen J and Strober W (2001) Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat. Immunol. 2: 223-228
34. Orange JS, Jain A, Ballas ZK, Schneider LC, Geha RS and Bonilla FA (2004) The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation. J. Allergy Clin. Immunol. 113: 725-733
35. Martinez-Pomar N, Muñoz-Saa I, Heine-Suñer D, Martin A, Smahi A and Matamoros N. Late skewed x-chromosome inactivation in incontinentia pigmenti female patient with immunodeficiency: A new mutation in NEMO gene exon 7. Hum. Genet. (in press)
36. Kaisho T and Akira S (2004) Pleiotropic function of Toll-like receptors. Microbes Infect. 6: 1388-1394
37. Orange JS, Brodeur SR, Jain A, Bonilla FA, Schneider LC, Kretschmer R, Nurko S, Rasmussen WL, Kohler JR, Gellis SE, Ferguson BM, Strominger JL, Zonana J, Ramesh N, Ballas ZK and Geha RS (2002) Deficient natural killer cell cytotoxicity in patients with IKK-γ/NEMO mutations. J. Clin. Invest. 109: 1501-1509
38. Pinheiro M and Freire-Maia N (1994) Ectodermal dysplasia: A clinical classification and a causal review. Am. J. Med. Genet. 53: 153-162
39. Kere J, Srivastava AK, Montonen O, Zonana J, Thomas N, Ferguson B, Ferguson B, Munoz F, Morgan D, Clarke A, Baybayan P, Chen EY, Ezer S, Saarialho-Kere U, de la Chapelle A and Schlessinger D (1996) X-linked anhidrotic (hypohidrotic) ectodermal dysplasia is caused by mutation in a novel transmembrane protein. Nat. Genet. 13: 409-416
40. Montonen O, Ezer S, Saarialho-Kere UK, Herva R, Karjalainen-Lindsberg ML and Kaitila I (1998) The gene defective in anhidrotic ectodermal dysplasia is expressed in the developing epithelium, neuroectoderm, thymus and bone. J. Histochem. Cytochem. 46: 281-289
41. Ezer S, Bayes M, Elomaa O, Schlessinger D and Kere J (1999) Ectodysplasin is a collagenous trimeric type II membrane protein with a tumour necrosis factor-like domain and co-localize with cytoskeletal structures at lateral and apical surfaces of cells. Hum. Mol. Genet. 8: 2079-2086
42. Mikkola ML, Pispa J, Pekkanen M, Paulin L, Nieminen P, Kere J and Thesleff I (1999) Ectodysplasin, a protein required for epithelial morphogenesis, is a novel TNF homologue and promotes cell-matrix adhesion. Mech. Dev. 88: 133-146
43. Chen Y, Molloy SS, Thomas L, Gambee J, Bachinger HP, Ferguson B, Zonana J, Thomas G and Morris NP (2001) Mutations within a furin consensus sequence block proteolytic release of ectodysplasin and cause X-linked hypohidrotic ectodermal dysplasia. Proc. Natl. Acad. Sci. USA 98: 7218-7223
44. Headon DJ and Overbeek PA (1999) Involvement of a novel Tnf receptor homologue in hair follicle induction. Nat Genet. 22: 370-374
45. Monreal AW, Ferguson BM, Headon DJ, Street SL, Overbeek PA and Zonana J (1999) Mutations in the human homologue of mouse dl cause autosomal recessive and dominant hypohidrotic ectodermal dysplasia. Nat Genet. 22: 366-369
46. Elomaa O, Pulkkinen K, Hannelius U, Mikkola M, Saarialho-Kere U and Kere J (2001) Ectodysplasin is released by proteolytic shedding and binds to the EDAR protein. Hum. Mol. Genet. 10: 953-962
47. Kumar A, Eby MT, Sinha S, Jasmin A and Chaudhary PM (2000) Ectodermal dysplasia receptor activates the nuclear factor κB, c-Jun N-terminal kinase and cell death pathways and binds to ectodysplasin A. J. Biol. Chem. 276: 2668-2677
48. Tucker AS, Headon DJ, Schneider P, Ferguson BM, Overbeek P, Tschopp J and Sharpe PT (2000) Edar/Eda interactions regulate enamel knot formation in tooth morphogenesis. Development 127: 4691-4700
49. Laurikkala J, Mikkola M, Mustonen T, Aberg T, Koppinen P, Pispa J, Nieminen P, Galceran J, Grosschedl R and Thesleff I (2001) TNF signaling via the ligand-receptor pair ectodysplasin and edar controls the function of epithelia signaling centers and is regulated by Wnt and activin during tooth organogenesis. Dev. Biol. 229: 443-455
50. Headon DJ, Emmal SA, Ferguson BM, Tucker AS, Justice MJ, Sharpe PT, Zonana J and Overbeek PA (2001) Gene defect in ectodermal dysplasia implicates a death domain adapter in development. Nature 414: 913-916
51. Yan M, Zhang Z, Brady JR, Schilbach S, Fairbrother WJ and Dixit VM (2002) Identification of a novel death domain-containing adaptor molecule for ectodysplasin-A receptor that is mutated in crinkled mice. Curr. Biol. 12: 409-413
52. Yan M, Wang LC, Hymowitz SG, Schilbach S, Lee J, Goddard A, de Vos AM, Gao WQ and Dixit VM (2000) Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distincts receptors. Science 290: 523-527
53. Mansour S, Woffendin H, Mitton S, Jeffery I, Jakins T, Kenwrick S and Murday VA (2001) Incontinentia pigmenti in a surviving male is accompanied by hypohidrotic ectodermal dysplasia and recurrent infection. Am. J. Med. Genet. 99: 172-177
54. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leopardi A, Tran T, Boyce BF and Siebenlist U (1997) Requirement for NF-κB in osteoclast and B-cell development. Genes Dev. 11: 3482-3496
55. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A and Bravo R (1997) Osteopetrosis in mice lacking nf-kappa-b1 and nf-kappa-b2. Nat. Med. 3: 1285-1289
56. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB and Boyle WJ (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96: 3540-3545
57. Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K and Finegold DN (2000) Missense mutations interfere with VEGFR-3 signaling in primary lymphoedema. Nat. Genet. 25: 153-159
58. Orange JS, Levy O, Brodeur SR, Krzewski K, Roy RM, Niemela JE, Fleisher TA, Bonilla FA and Geha RS (2004) Human nuclear factor kappa B essential modulator mutation can result in immunodeficiency without ectodermal dysplasia. J. Allergy Clin. Immunol. 114: 650-656
59. Niehues T, Reichenbach J, Neubert J, Gudowius S, Puel A, Horneff G, Lainka E, Dirksen U, Schroten H, Doffinger R, Casanova JL and Wahn V (2004) Nuclear factor kappaB essential modulator-deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia. J. Allergy Clin. Immunol. 114: 1456-1462
60. Tobin E, Rohwedder A, Holland SM, Philips B and Carlson JA (2003) Recurrent 'sterile' verrucous cyst abscesses and epidermodysplasia verruciformis-like eruption associated with idiopathic CD4 lymphopenia. Br. J. Dermatol. 149: 627-633
61. Courtois G, Smahi A, Reichenbach J, Doffinger R, Cancrini C, Bonnet M, Puel A, Chable-Bessia C, Yamaoka S, Feinberg J, Dupuis-Girod S, Bodemer C, Livadiotti S, Novelli F, Rossi P, Fischer A, Israël A, Munnich A, Le Deist F and Casanova JL (2003) A hypermorphic IκBα mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J. Clin. Invest. 112: 1108-1115
62. Janssen R, van Wengen A, Hoeve MA, ten Dam M, van der Burg M, van Dongen J, van de Vosse E, van Tol M, Bredius R, Offenhoff TH, Weemaes C, van Dissel JT and Lankester A (2004) The same IκBα mutation in two related individuals leads to completely different clinical syndromes. J. Exp. Med. 200: 559-568
63. Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, Green H, Brown C, Biggs PJ, Lakhani SR, Jones C, Hansen J, Blair E, Hofmann B, Siebert R, Turner G, Evans DG, Schrander-Stumpel C, Beemer FA, van Den Ouweland A, Halley D, Delpech B, Cleveland MG, Leigh I, Leisti J and Rasmussen S (2000) Identification of the familial cylindromatosis tumour-suppressor gene. Nat. Genet. 25: 160-165
64. Poblete Gutierrez P, Eggermann T, Holler D, Jugert FK, Beermann T, Grussendorf-Conen EI, Zerres K, Merk HF and Frank J (2002) Phenotype diversity in familial cylindromatosis: A frameshift mutation in the tumor suppressor gene CYLD underlies different tumors of skin appendages. J. Invest. Dermatol. 119: 527-531
65. Zheng G, Hu L, Huang W, Chen K, Zhang X, Yang S, Sun J, Jiang Y, Luo G and Kong X (2004) CYLD mutation causes multiple familial trichoepithelioma in three Chinese families. Hum. Mutat. 23: 400
66. Zhang XJ, Liang YH, He PP, Yang S, Wang HY, Chen JJ, Yuan WT, Xu SJ, Cui Y and Huang W (2004) Identification of the cylindromatosis tumor-suppressor gene responsible for multiple familial trichoepithelioma. J. Invest. Dermatol. 122: 658-664
67. Salhi A, Bornholdt D, Oeffner F, Malik S, Heid E, Happle R and Grzeschik KH (2004) Multiple familial trichoepithelioma caused by mutations in the cylindromatosis tumor suppressor gene. Cancer Res. 64: 5113-5117
68. Kovalenko A, Chable-Bessia C, Cantarella G, Israël A, Wallach D and Courtois G (2003) The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination. Nature 424: 801-805
69. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A and Mosialos G (2003) CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature 424: 793-796
70. Regamey A, Hohl D, Liu JW, Roger T, Kogerman P, Toftgard R and Huber M (2003) The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor. J. Exp. Med. 198: 1959-1964
71. Brummelkamp TR, Nijman SM, Dirac AM and Bernards R (2003) Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 424: 797-801
72. Chen ZJ (2005) Ubiquitin signalling in the NF-κB pathway Nature Cell. Biology 7: 758-765
73. Reiley W, Zhang M and Sun SC (2004) Negative regulation of JNK signaling by the tumor suppressor CYLD. J. Biol. Chem. 279: 55161-55167
74. Suzuki N, Suzuki S and Yeh WC (2002) IRAK-4 as the central TIR signaling mediator in innate immunity. Trends Immunol. 23: 503-506
75. Picard C, Puel A, Bonnet M, Ku C-L, Bustamante J, Yang K, Soudais C, Dupuis S, Feinberg J, Fieschi C, Elbim C, Hitchcock R, Lammas D, Davies G, Al-Ghonaium A, Al-Rayes H, Al-Jumaah S, Al-Hajjar S, Al-Mohsen IZ, Frayha HH, Rucker R, Hawn TR, Aderem A, Tufenkeji H, Haraguchi S, Day NK, Good RA, Gougerot-Pocidalo MA, Ozinsky A and Casanova JL (2003) Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299: 2076-2079
76. Medvedev AE, Lentschat A, Kuhns DB, Blanco JCG, Salkowski C, Zhang S, Arditi M, Gallin JI and Vogel SN (2003) Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysacharide and interleukin-1 in a patient with recurrent bacterial infections. J. Exp. Med. 198: 521-531